Patents and exclusivity work in a similar fashion but are distinct from one another and governed by different statutes. Patents are a property right granted by the United States Patent and Trademark Office anytime during the development of a drug and can encompass a wide range of claims. Every year many top pharmaceutical industries are losing patent rights or exclusivity of their research molecules. And it hits their business module effectively which drives big pharmaceutical industries to engage in research continuously.
In 2019, Lyrica (Pfizer) and Herceptin (Genentech) were exclusive molecules which lost their patents. And same way many expected for this year 2020. Top 10 brands will include market of around USD 8 Billion. And Indian generic pharmaceutical industries have chance to enter in this market.
Below, list of top 10 brands are given which patent is expiring in 2020
10. Proair HFA
Company: Teva
Treatment: treatment or prevention of bronchospasm
2019 USA sales: USD 274 million
Generic launched: Feb. 25, 2020
9. Risperdal Consta
Company: Johnson & Johnson and Alkermes
Treatment: schizophrenia and bipolar I disorder
2019 USA sales: USD 314 million
Patent expiration: Nov. 2020
8. Kuvan
Company: BioMarin
Treatment: phenylketonuria
2019 global sales: USD 463 million
Generics expected: 2020
7. Ciprodex
Company: Novartis
Treatment: ear infections
2019 USA sales: USD 470 million (estimate)
Generics expected: 2020
6. Atripla
Company: Gilead
Treatment: HIV
2019 USA sales: USD 501 million
Generics expected: 2020
5. Forteo
Company: Eli Lilly
Treatment: osteoporosis
2019 USA sales: USD 645 million
Biosimilar expected: 2020
4. NuvaRing
Company: Merck & Co.
Treatment: contraception
2019 USA sales: USD 742 million
Generics launched: Dec. 12, 2019
3. Chantix
Company: Pfizer
Treatment: smoking cessation
2019 USA sales: USD 899 million
Main patent expiration: November 2020
2. Afinitor
Company: Novartis
Treatment: various cancers
2019 USA sales: USD 1 billion
Generics launched: Dec. 10, 2019
1. Truvada
Company: Gilead Sciences
Treatment: HIV
2019 USA sales: USD 2.64 billion
Generics expected: Soon
It is interesting to see moves from Indian Pharmaceutical industries.
.png)
